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Edited to Lukas HuberAbstract Roscovitine is a potent CDK inhibitor often used as a
biological tool in cell-cycle studies, but its working mechanism
and real targets in vascular smooth muscle cells (VSMCs) re-
main unclear. In this study, we observed that ERK1/2 phosphor-
ylation induced by Ang II was abrogated by pretreating VSMCs
with roscovitine for 15 h. Pretreating VSMCs with roscovitine
also inhibited Ang II-induced c-Jun expression and phosphoryla-
tion. We further demonstrated that roscovitine could suppress
the DNA binding activity of c-Jun and activation of angiotensin-
ogen promoter by Ang II. These results suggest that roscovitine
represses Ang II-induced angiotensinogen expression by inhibit-
ing activation of ERK1/2 and c-Jun.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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R-roscovitine (CYC202) is a potent CDK2/cyclin E inhibitor
undergoing phase-2 clinical testing against lung and breast
cancer, and phase-1 clinical trials against glomerulonephritis.
Besides its use as a potential drug to treat cancer, neurodegen-
erative diseases, viral infections, and glomerulonephritis, ros-
covitine is also often used as a biological tool in the studies
of cell cycle, neuronal function and apoptosis. Previous studies
have suggested that molecular targets of R-roscovitine are
clearly very diﬀerent in the diﬀerent cell types. For examples,
roscovitine prevented the tyrosine phosphorylation and conse-
quent activation of signal transducer and activator of tran-
scription (STAT) 5 in HTLV-1-transformed T-cell line MT-2
[1]. Treatment of human colon carcinoma cell lines with rosco-
vitine decreased both retinoblastoma protein phosphorylation
and total retinoblastoma protein, and increased the phosphor-
ylation of extracellular signal-regulated kinase (ERK) 1/2 [2].
Roscovitine was also shown to inhibit RNA synthesis in hu-
man cells probably by mechanisms other than CDK inhibitionAbbreviations: VSMCs, vascular smooth muscle cells; Ang II, angio-
tensin II; FBS, fetal bovine serum; DMSO, dimethyl sulfoxide; ERK1/
2, extracellular signal-regulated kinase1/2; STAT5, signal transducer
and activator of transcription 5
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doi:10.1016/j.febslet.2007.12.011[3]. In addition, the eﬀect of roscovitine on voltage-activated
calcium channels in central neurons was reported to be inde-
pendent of cdk5 inhibition [4]. Although considerable data
have accumulated with respect to the eﬀects of roscovitine
on a large diversity of cellular models, the working mechanism
and real targets of roscovitine in vascular smooth muscle cells
(VSMCs) remain unclear. Our recent study showed that rosco-
vitine signiﬁcantly inhibited VSMC proliferation stimulated by
angiotensin II (Ang II) or fetal bovine serum (FBS). To further
elucidate the molecular mechanism, the present study tested its
eﬀects on ERK1/2 pathway activation and consequent regula-
tion of downstream transcription factor c-Jun. Our results sug-
gest that roscovitine not only inhibits ERK1/2 and c-Jun
phosphorylation, but also suppresses the c-Jun expression in-
duced by Ang II, which leads to negative regulation of the pre-
cursor molecule-angiotensinogen.2. Materials and methods
2.1. Materials
Roscovitine, Ang II, PD98059 and dimethyl sulfoxide (DMSO) were
purchased from Sigma Chemical Co. (St. Louis, MO, USA). Protein
A-agarose, Enhanced chemiluminescence (ECL) reagent, Antibodies
for phospho-ERK1/2 (Tyr204), ERK1/2, phosphoserine, c-Jun and
STAT5b were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Non-radioactive p44/42 MAP Kinase Assay Kit was pur-
chased from Cell Signaling Technology (Danvers, MA, USA). Dul-
beccos modiﬁed Eagles medium (DMEM) and FBS were purchased
from Gibco-BRL (Rockville, MD, USA). Trizol reagent was pur-
chased from Invitrogen (Carlsbad, CA). Roscovitine and PD98059
were dissolved in DMSO and diluted to diﬀerent concentrations
with serum-free DMEM before experiments, and the ﬁnal concentra-
tion of DMSO was kept below 0.01% (v/v) in any of the experiments.
Other chemical reagents not mentioned were all from Sigma Chemical
Co.
2.2. Cell culture
VSMCs were isolated from the thoracic aorta of 90–110 g male
Sprague–Dawley rats as described previously [5]. Cells were grown in
DMEM supplemented with 10% FBS, 100 U/ml penicillin, and
100 lg/ml streptomycin. Cultures were maintained at 37 C in a
humidiﬁed 95% air and 5% CO2 atmosphere. After the ﬁrst subculture,
cells were subcultured with 0.25% trypsin every 3–4 days. The purity of
VSMC culture was identiﬁed morphologically and conﬁrmed with
immunocytochemical staining.
2.3. Whole and nuclear extract preparation
VSMCs were stimulated with Ang II (100 nM) at 37 C for 5, 10,
30 min or 1, 3 h, then cell extracts were prepared. Whole-cell lysates
were extracted from VSMCs as described previously [6]. Upon termi-
nation of culture, VSMCs were washed three times with PBS and lysed
in lysis buﬀer ( 50 mM Tris–HCl, pH 7.2, 150 mM NaCl, 40 mM NaF,
0.1% sodium deoxycholate, 1% Triton X-100, 5 mM EDTA, 5 mMation of European Biochemical Societies.
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4 C for 30 min. The lysates were centrifuged at 8000 rpm for 10 min
(4 C). The supernatants were used to analyze the expression of
ERK and p-ERK. Nuclear proteins were extracted from VSMCs
according to a modiﬁed Dignams method [7]. After collecting the cells
and removing the medium, the cells were washed with ice-cold PBS
and lysed on ice in a buﬀer A (10 mM HEPES, pH 7.9, 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM PMSF)
for 15 min with occasional vortexing. After addition of NP-40 (0.6%),
the lysates were centrifuged at 12000 rpm and supernatants were
removed (cytoplasmic extracts). The pellets were resuspended in buﬀer
B (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 0.1 mM
EGTA, 0.5 mM dithiothreitol, and protease inhibitors) and incubated
at 4 C for 40 min. The nuclear protein extracts were isolated by
centrifugation at 12000 rpm for 10 min. Then the proteins were
determined by a modiﬁed Lowry protein assay and used to analyze
c-Jun, p-c-Jun and STAT5b.2.4. Immunoprecipitations and Western blot analysis
Equal amounts of proteins (50–100 lg) were separated by 8–12%
SDS–PAGE, and electro-transferred to a PVDF membrane. Mem-
branes were blocked in 5% BSA for 2 h at room temperature, and incu-
bated overnight at 4 C with primary antibodies: anti-phospho-ERK1/
2 (1:400), anti-ERK1/2 (1:400), anti-phosphoserine (1:1000), anti-c-Jun
(1:500) or anti-STAT5b (1:500), then with respective secondary anti-
bodies at room temperature for 2 h. Thereafter, proteins were visual-
ized using the ECL detection system, and protein abundance was
quantiﬁed by densitometry analysis (Kodak-Imager 1D). Immunopre-
cipitations were performed as described previously [8]. Brieﬂy, cell ex-
tracts were ﬁrst pre-cleared with 20 ll of protein A-agarose (50% v/v).
The supernatants were immunoprecipitated with 1–2 lg of anti-phos-
phoserine antibodies. Protein A-agarose–antigen–antibody complexes
were collected by centrifugation at 12000 rpm for 20 s at 4 C. Immu-
noprecipitates were washed three times with washing buﬀer and then
separated by SDS–PAGE and immunoblotted with antibodies as indi-
cated. The experiments were replicated three times at least.
2.5. RT-PCR
Total RNA was isolated from cultured cells using Trizol reagent
(Invitrogen) according to the manufacturers instruction. RNA con-
centration and quality were assessed spectrophotometrically at wave
lengths 260 and 280 nm. Reverse transcription reaction was performed
with oligo(dT) primers and MMLV (Promega). Equal amount of RNA
was used as templates in each reaction. PCR was performed with stan-
dard methods. The primers for rat c-jun were 5 0-ATGGTCGCT-
CCCGCT-30 and 5 0-GCTGTGCCACCTGTTCC-3 0. The primers
used for rat beta-actin were 5 0-CAGGGTGTGATGGTGGG-3 0 and
5 0-GGAAGAGGATGCGGCAG-3 0.
The PCR protocol was as follows: 94 C for 5 min, then 25 cycles at
94 C for 30 s, 56 C for 40 s and 72 C for 40 s, followed by 72 C for
10 min. The PCR products were separated on 1% agarose gel. The
mRNA of angiotensinogen gene was detected as described previously
[9].
2.6. Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assays were performed as described
previously [10] with modiﬁcations. Brieﬂy, cross-linking was accom-
plished via the addition of formaldehyde (1% ﬁnal concentration) for
20 min at room temperature. The cultures were then quenched by add-
ing glycine to 125 mM for 5 min at room temperature. The ﬁxed cells
were washed twice in ice-cold PBS and cells were collected by centrifu-
gation. Cells were sonicated eight times for 20 s each with 1 min inter-
vals on ice. After sonication, the chromatin solutions were precleared
with protein A-agarose and salmon sperm DNA, and subjected to
immunoprecipitation (IP) by incubating with anti-c-Jun antibody, fol-
lowed by incubation with protein A-agarose-salmon sperm DNA. No
antibody was used as a negative control. After serial washes, precipi-
tated chromatin was eluted and cross-linking was reversed with
0.3 M NaCl; protein was removed using proteinase K; chromatin
was then puriﬁed by phenol-chloroform extraction and ethanol precip-
itation. PCR was performed using primers spanned 644 to 181 of
the angiotensinogen promoter, which includes the AP-1 sites. The pri-
mer sequence was 5 0-ACTCAAGGGCGGTGCTCTGA-3 0 and 5 0-
TGGCAGATGAGCTTCAGGCA-3 0.2.7. Construction of reporter plasmid, cell transfection and reporter gene
assay
The DNA fragments of the angiotensinogen promoter region (545
to +39), containing AP-1 sites, were generated by PCR ampliﬁcation
from genomic DNA and cloned into pGL3-Basic (Promega), and
authenticity was veriﬁed by sequencing. For luciferase reporter assay,
exponentially growing VSMCs were plated in 12-well culture dishes.
Transfections were carried out using Lipofectamine 2000 (Invitrogen)
according to the manufacturers instructions. Reagent amounts used
per well were 0.5 lg of pRL-TK, 1 lg of luciferase reporter plasmid,
3 ll of Lipofectamine 2000, and 2 ml of 2% serum-containing DMEM.
Twenty-four hours after transfection, cells were treated with roscovi-
tine (30 lM) for 15 h or PD98059 (30 lM) for 1 h, followed by stimu-
lation with Ang II (100 nM) for 24 h. Cell lysates were harvested, and
then luciferase activity was assayed using the dual-luciferase reporter
assay system (Promega) according to the manufacturers instructions.
All transfections were performed in quadruplicate.2.8. In vitro ERK kinase activity assay
ERK1/2 activity was determined using a non-radioactive ERK1/2
activity assay kit from cell signaling according to the manufacturers
instructions. Brieﬂy, the active phosphorylated ERK1/2 from cell
lysates of the Ang II-treated VSMCs for 5 min was immunoprecipi-
tated with phospho-ERK1/2 (Thr202/Tyr204) mouse mAb. The result-
ing immunoprecipitate was then incubated with an Elk-1 fusion
protein in the presence of ATP and roscovitine (30 lM) or PD98059
(30 lM). Phosphorylation of Elk-1 was measured by Western blotting
analysis using an anti-phospho-Elk-1 antibody (1:1000) or anti-phos-
pho-ERK1/2 antibody (1:400) (as loading control).2.9. Statistical analysis
Results are expressed as means ± S.D., and an analysis of variance
with Bonferronis test was used for the statistical analysis of multiple
comparisons of data. P-values less than 0.05 were considered statisti-
cally signiﬁcant.3. Results
3.1. Roscovitine inhibits Ang II-induced ERK1/2
phosphorylation and kinase activity in VSMCs
Ang II has been shown to stimulate VSMC proliferation by
activating the ERK1/2 pathway and inducing the expression of
Fos and Jun-related proteins [11,12]. We found that Ang II-in-
duced VSMC proliferation could be inhibited by roscovitine
(data not shown). To identify the molecular targets in roscovi-
tine-inhibited VSMC proliferation, we investigated the eﬀect of
roscovitine on Ang II-induced ERK1/2 phosphorylation. As
shown in Fig. 1A, total ERK1/2 was not changed after treating
with 100 nM Ang II or/and 30 lM roscovitine for 5–30 min;
however, ERK1/2 phosphorylation was observed very strong
after 5 min of Ang II treatment, which falls slightly at 10
and 30 min but still remains above basal level. ERK1/2 phos-
phorylation induced by Ang II was completely inhibited by
pretreating VSMCs with roscovitine for 15 h, indicating that
roscovitine could potently suppress Ang II-induced ERK1/2
activation.
To determine the functional signiﬁcance of roscovitine-
inhibited ERK1/2 phosphorylation in VSMCs, the phosphory-
lation of c-Jun, a downstream protein of ERK1/2 pathway,
was assessed by anti-phospho-c-Jun mAb. As expected, Ang
II increased c-Jun phosphorylation after 5, 10, 30 min of treat-
ment, whereas roscovitine prevented such induction (Fig. 1A).
The phosphorylation of c-Jun was further assessed by immu-
noprecipitating with anti-phospho-ser mAb and immunoblot-
ting with anti-c-Jun antibody. Result indicated that Ang
II-induced c-Jun phosphorylation at 30 min of treatment was
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Fig. 1. Eﬀect of roscovitine on Ang II-induced ERK1/2 and c-Jun phosphorylation in VSMCs. (A) Growth-arrested VSMCs were pretreated without
or with roscovitine (30 lM) for 15 h before stimulation with Ang II (100 nM) for 0, 5, 10, 30 min. The whole cell lysates were analyzed by Western
blotting with antibody against ERK1/2, phospho-ERK1/2 or phospho-c-Jun. Coomassie Blue (CB) staining is included as loading control. (B)
Growth-arrested VSMCs were pretreated without or with roscovitine (30 lM) for 15 h before stimulation with Ang II (100 nM) for 0 and 30 min, cell
extracts were immunoprecipitated with antibody to phosphoserine and immunoblotted with antibody to c-Jun. (C) Growth-arrested VSMCs were
pretreated with or without roscovitine (30 lM) for 15 h, and then treated with or without Ang II (100 nM) for 30 min, the levels of ERK1/2,
phospho-ERK1/2 or c-Jun were detected by Western blotting. (D) VSMCs were stimulated by Ang II for 5 min. Cell lysate was used to
immunoprecipitate active phosphorylated ERK1/2 using an anti-phospho-ERK1/2 monoclonal antibody. The ERK1/2 activity was determined in
the presence of roscovitine (30 lM) or PD98059 (30 lM), using the GST-Elk fusion protein as a substrate, by Western blotting with anti-phospho-
Elk-1 antibody. Phospho-ERK1/2 was used as loading control. All results are repeated for three times.
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ylation of ERK1/2 and expression of c-Jun were not aﬀected
by roscovitine-treatment alone, but their inductions by Ang
II were signiﬁcantly inhibited by pretreating VSMCs with ros-
covitine (Fig. 1C).
As expected, in vitro ERK kinase assay using Elk-1 as a sub-
strate of ERK1/2 showed that the activity of Ang II-activated
ERK1/2 that was precipitated from cell lysates was inhibited
by roscovitine and ERK1/2 inhibitor PD98059 as evidenced
by decreased phosphorylation of Elk-1 (Fig. 1D). This obser-
vation is consistent with the notion that roscovitine completely
blocked Ang II-induced ERK1/2 phosphorylation (Fig. 1A).
These results clearly demonstrate that roscovitine directly
inhibits ERK1/2 kinase activity by blocking ERK1/2 phos-
phorylation.3.2. Inhibition of ERK1/2 phosphorylation by roscovitine causes
down-regulation of c-Jun at the mRNA and protein levels
To determine whether inhibition of ERK1/2 phosphoryla-
tion by roscovitine aﬀects c-Jun expression, VSMCs were trea-
ted with increasing concentration of roscovitine (0–45 lM) for
15 h, and then stimulated with 100 nM Ang II for 30 min. As
shown in Fig. 2A, roscovitine resulted in a concentration-
dependent inhibition of the c-Jun expression induced by Ang
II. Densitometric analysis of the Western blots was performed,
and abundance of c-Jun protein decreased by 29.5% at 15 lM
roscovitine, 51.9% at 30 lM roscovitine, and 78.4% at 45 lM
roscovitine, respectively. Exposure of VSMCs to 15, 30,
45 lM roscovitine for 15 h had no eﬀect on the expression of
STAT5b (data not shown), suggesting that the inhibition of
c-Jun expression by roscovitine is speciﬁc.
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Fig. 2. Inhibition of c-Jun expression by roscovitine. (A) Arrested VSMCs were pretreated for 15 h without or with roscovitine at concentration of 0
to 45 lM, and stimulated with Ang II (100 nM) for 30 min. Amounts of c-Jun was determined by Western blotting. (B) VSMCs received 30 lM
roscovitine for the indicated time, and then stimulated with Ang II (100 nM) for 30 min. c-Jun protein was determined by Western blotting. (C)
Arrested VSMCs were pretreated without or with 30 lM roscovitine for 15 h, and then stimulated with Ang II (100 nM) for indicated times. Nuclear
proteins were analyzed by Western blotting with anti-c-Jun and anti-STAT5b antibodies as indicated. (D) Arrested VSMCs were pretreated without
or with 30 lM roscovitine for 15 h, and then stimulated with Ang II (100 nM) for 30 min. Total RNA was extracted, and the amounts of c-jun
mRNA were measured by quantitative RT-PCR (25 circles). b-Actin was used as internal controls. The ﬁgure is a representative of three independent
experiments. All results are repeated for three times.
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sion after pretreatment with 30 lM roscovitine from 2 to 24 h.
The c-Jun protein fell slightly after 8 h of roscovitine pretreat-
ment, was barely detectable at 12 h, and rose slightly again at
24 h compared to 12 h. When VSMCs were pretreated with
30 lM roscovitine for 15 h, and then stimulated by Ang II
for 30 min, 1 h, or 3 h, the c-Jun protein was markedly de-
creased (Fig. 2C). The decrease in c-Jun mRNA level caused
by roscovitine is consistent with roscovitine-induced change
at protein level, whereas the internal control, b-actin mRNA,
was not aﬀected by Ang II or/and roscovitine at all
(Fig. 2D). Immunocytochemistry staining also shows that
Ang II-induced c-Jun expression was inhibited by pretreating
VSMCs with roscovitine (data not shown). Expression level
of STAT5b was unaﬀected by roscovitine under the same con-
dition (Fig. 2). These ﬁndings show that roscovitine selectively
down-regulates c-Jun expression at mRNA and protein levels
in VSMCs.
3.3. Roscovitine inhibits AP-1 DNA binding activity and
angiotensinogen expression induced by Ang II
The transcription factor AP-1, a dimeric complex consist-
ing of c-Jun and c-Fos, is a major target of the ERK1/2,
and regulates the expression of growth-responsive genes
including angiotensinogen gene. Our previous study showed
that Ang II induces its precursor gene expression by phos-phorylating c-Jun and activating AP-1 [9]. To determine
whether the inhibition of ERK1/2 and c-Jun phosphorylation
by roscovitine aﬀects the binding of AP-1 to its cis-element,
ChIP assays were performed. VSMCs were treated with form-
aldehyde to cross-link chromatin to associated proteins.
Chromatin DNA was immunoprecipitated with anti-c-Jun
antibody, and recovered DNA was analyzed by PCR using
primers speciﬁc for the angiotensinogen promoter containing
AP-1 binding site. As shown in Fig. 3A, AP-1 binding se-
quence could be detected in the immunoprecipitates pulled
by anti-c-Jun antibody. An increased binding of c-Jun to
the angiotensinogen promoter was observed in VSMCs trea-
ted by Ang II alone. Roscovitine eﬀectively suppressed the
DNA binding activity of c-Jun induced by Ang II. Fig. 3B
shows the eﬀect of roscovitine on angiotensinogen expression.
The transcripts of angiotensinogen gene were down-regulated,
as demonstrated by RT-PCR, by treating VSMCs with
roscovitine for 15 h. The angiotensinogen promoter-reporter
activity assay indicated that Ang II signiﬁcantly induced
activation of angiotensinogen promoter, and pretreating
VSMCs with roscovitine or PD98059, an ERK1/2 inhibitor,
reduced Ang II-induced activation of this promoter by 33%
and 55%, respectively (Fig. 3C). These ﬁndings suggest
that roscovitine suppresses angiotensinogen expression by
blocking ERK1/2 pathway and inhibiting c-Jun phosphoryla-
tion.
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Fig. 3. Eﬀect of roscovitine on Ang II-induced angiotensinogen expression in VSMCs. (A) Roscovitine blocks Ang II-induced binding of AP-1 to
angiotensinogen promoter. VSMCs were treated with vehicle or roscovitine (30 lM) for 15 h. Chromatin fragments were immunoprecipitated with
antibody against c-Jun, and the angiotensinogen promoter region (644 to 181) was ampliﬁed by PCR. (B) Inhibition of angiotensinogen
expression by roscovitine. Arrested VSMCs were pretreated without or with 30 lM roscovitine for 15 h, and then stimulated with Ang II (100 nM)
for 3 h. Total RNA was extracted; and the amounts of angiotensinogen mRNA was measured by quantitative RT-PCR. GAPDH was used as
internal controls. (C) Roscovitine inhibits Ang II-induced angiotensinogen promoter activation. VSMCs were transiently transfected with an equal
amount of angiotensinogen promoter-reporter plasmids for 24 h, and then stimulated with Ang II (100 nM) for 24 h in the presence of roscovitine
(30 lM) or PD98059 (30 lM, as positive control). Luciferase activity was determined using the dual-luciferase reporter assay system and normalized
by cotransfection of pRL-TK plasmid. The data are presented as means ± S.E. (n = 4).
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Previous studies have demonstrated that roscovitine, a spe-
cial inhibitor of CDK2, could eﬀectively block cell cycle pro-
gression of diﬀerent cell types [13,14]. The recent study
showed that roscovitine could inhibit VSMC proliferation
through both pRb-dependent and independent pathways
[15], but without elucidation of a satisfactory mechanism. In
the present study, we found that roscovitine-elicited inhibition
of VSMC proliferation was attributed to blockade of ERK1/2
signaling.
To further explore the molecular mechanism by which ros-
covitine inhibits VSMC proliferation, we investigated the eﬀect
of roscovitine on Ang II-induced signal transduction pathways
in VSMCs. ERK1/2 has been reported to be activated by Ang
II in VSMCs [16]. Moreover, PD98059, a speciﬁc inhibitor of
MEK-ERK1/2 pathway, has been shown to block the VSMC
proliferation induced by Ang II [17]. Recent study showed that
ERK1/2 pathway was involved in the inhibitory eﬀect of croce-
tin on Ang II-induced VSMC proliferation [18]. These results
implied that ERK1/2 pathway might be critical for VSMC pro-
liferation. In our study, VSMCs were pretreated by roscovi-
tine, and then stimulated with Ang II, the results showed
that roscovitine signiﬁcantly inhibited the ERK1/2 phosphory-lation and its kinase activity directly induced by Ang II in
VSMCs. We ﬁrst demonstrated that roscovitine could com-
pletely abrogate ERK1/2 activation in Ang II-stimulated
VSMCs. This ﬁnding is coincident with a recent report which
showed that high concentration of roscovitine inhibits ERK 1/
2 phosphorylation in normal human keratinocytes [19], and in
contrast to previous reports which showed that roscovitine in-
duces ERK1/2 phosphorylation in human colon cancer cells
[2]. This is a good example that such an inhibitory compound
may have opposite eﬀects in normal versus cancer cells. These
observations strongly suggest that the eﬀects of roscovitine
should ideally be tested in diﬀerent experimental systems in or-
der to be better understood.
The activation of MAPK is associated with VSMC prolifer-
ation due to stimulating the expression of downstream growth-
responsive genes c-Jun, c-Fos and Elk-1, subsequently increas-
ing DNA synthesis of VSMCs [11,12]. The c-Jun expression
and activity are partly regulated by MAPK, and c-Jun is a ma-
jor component of transcription factor AP-1 [20,21]. AP-1 is
known to autoregulate c-jun expression by binding to the
AP-1 site present within the c-jun promoter [22]. As a down-
stream target of MAPK, c-Jun is activated by phosphorylation
on Ser63 and Ser73. The activation of c-Jun forms AP-1, and
regulates the expression of genes involving in cell proliferation,
248 A.-Y. Li et al. / FEBS Letters 582 (2008) 243–248including itself expression. In this study, we demonstrated that
roscovitine reduced c-Jun expression and phosphorylation in-
duced by Ang II. These results further elucidate the mechanism
of roscovitine-inhibiting c-Jun expression in VSMCs.
Our previous study showed that c-Jun was involved in Ang
II-induced angiotensinogen expression [9]. We next investi-
gated the eﬀect of roscovitine on angiotensinogen gene expres-
sion and mechanism by which roscovitine suppressed Ang II-
induced angiotensinogen gene expression. RT-PCR results
showed that roscovitine reduced angiotensinogen gene expres-
sion. ChIP assays indicated that roscovitine blocked Ang II-
mediated induction of angiotensinogen expression by sup-
pressing the binding of c-Jun to the angiotensinogen promoter.
Importantly, these results are consistent with our previous re-
ports that the induction of angiotensinogen transcription by
Ang II could be blocked by antagonizing AP-1 [9]. Luciferase
reporter assay showed that roscovitine could signiﬁcantly inhi-
bit angiotensinogen promoter activation induced by Ang II.
ERK-speciﬁc inhibitor PD98059 could also block Ang II-med-
iated angiotensinogen induction. These results suggest that
Ang II-activated ERK1/2 activation promotes c-Jun phos-
phorylation, leading to angiotensinogen promoter transactiva-
tion, whereas roscovitine suppresses Ang II-induced
angiotensinogen expression via inhibiting ERK1/2 phosphory-
lation and its kinase activity.
In conclusion, we show that roscovitine signiﬁcantly inhibits
Ang II-induced VSMC proliferation and c-Jun expression,
which was associated with the inhibition of ERK1/2 signal
pathway. Our data provided a possible molecular mechanism
whereby the inhibitive eﬀect of roscovitine on VSMCs prolifer-
ation was mediated. This study provided the ﬁrst evidence that
roscovitine could inhibit ERK1/2 phosphorylation and block
the c-Jun induction and activation, resulting in reduced levels
of c-Jun mRNA and protein in VSMCs. Roscovitine also
blocked Ang II-induced its precursor gene expression. The re-
sults also give an evidence that roscovitine may be feasible and
eﬀective in treating cardiovascular diseases such as atheroscle-
rosis and restenosis.Acknowledgements: This work is supported by the National Natural
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